Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties
Lara Sharpe, Justin Sinclair, Andrew Kramer, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada
Janni Leung, Gary Chan, Daniel Stjepanović, et al.
Psychopharmacology (2022) Vol. 239, Iss. 5, pp. 1509-1519
Open Access | Times Cited: 85
Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review
Deborah S. Hasin, Claire Walsh
Journal of Clinical Medicine (2020) Vol. 10, Iss. 1, pp. 15-15
Open Access | Times Cited: 84
Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis
Tory R. Spindle, C. Austin Zamarripa, Ethan B. Russo, et al.
Drug and Alcohol Dependence (2024) Vol. 257, pp. 111267-111267
Closed Access | Times Cited: 10
Development of cannabidiol derivatives as potent broad-spectrum antibacterial agents with membrane-disruptive mechanism
Shanfang Fang, Wen-Tyng Kang, Haizhou Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116149-116149
Closed Access | Times Cited: 9
PTSD, distress and substance use in the aftermath of October 7th, 2023, terror attacks in Southern Israel
Daniel L. Feingold, Yuval Neria, Dana Tzur Bitan
Journal of Psychiatric Research (2024) Vol. 174, pp. 153-158
Closed Access | Times Cited: 9
Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study
Daniel T. Myran, Lyndsay D. Harrison, Michael Pugliese, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102455-102455
Open Access | Times Cited: 7
Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry
Raphael Rifkin‐Zybutz, Simon Erridge, Carl Holvey, et al.
Psychopharmacology (2023) Vol. 240, Iss. 8, pp. 1735-1745
Open Access | Times Cited: 19
Effects of inhaled cannabis high in Δ9-THC or CBD on the aging brain: A translational MRI and behavioral study
Aymen H. Sadaka, Justin Canuel, Marcelo Febo, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 18
Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study
Lara Bapir, Simon Erridge, Martha Nicholas, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 3, pp. 281-295
Open Access | Times Cited: 18
Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression
Giulia De Feo, Amy A. Case, Gregory B. Crawford, et al.
Supportive Care in Cancer (2023) Vol. 31, Iss. 3
Closed Access | Times Cited: 18
Stronger together: Coping behaviours and mental health changes of Canadian adolescents in early phases of the COVID-19 pandemic
Negin A. Riazi, Kate Battista, Markus J. Duncan, et al.
BMC Public Health (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Cannabis use in the UK: a quantitative comparison of individual differences in medical and recreational cannabis users
Beata Ciesluk, Simon Erridge, Mikael H. Sodergren, et al.
Frontiers in Psychology (2024) Vol. 14
Open Access | Times Cited: 5
Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms
Ethan B. Russo, Carrie Cuttler, Ziva D. Cooper, et al.
Cannabis and Cannabinoid Research (2021) Vol. 7, Iss. 5, pp. 706-716
Closed Access | Times Cited: 36
Opposing retrograde and astrocyte-dependent endocannabinoid signaling mechanisms regulate lateral habenula synaptic transmission
Nathan D. Winters, Veronika Kondev, Niharika Loomba, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112159-112159
Open Access | Times Cited: 15
Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review
Lauren Rice, Lisa Cannon, Navin Dadlani, et al.
European Child & Adolescent Psychiatry (2023) Vol. 33, Iss. 2, pp. 505-526
Open Access | Times Cited: 13
The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors
Kelly A. Sagar, Staci A. Gruber
CNS Drugs (2025)
Closed Access
The Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test
Marta Kruk-Słomka, Agnieszka Dzik, Grażyna Biała
Molecules (2025) Vol. 30, Iss. 4, pp. 867-867
Open Access
Adding Nuance to Understanding the Effects of Cannabis Legalization by Using Policy Bundles: A Study of Youth Mental Health
Shazib Altaf, Daniel J. Mallinson, Mingean Park, et al.
Substance Use & Misuse (2025), pp. 1-10
Open Access
Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products
Cassidy R. LoParco, Carlton Bone, Ashvita Garg, et al.
Journal of Psychoactive Drugs (2025), pp. 1-11
Closed Access
Self-Reported Effects of Cannabis on ADHD Symptoms, ADHD Medication Side Effects, and ADHD-Related Executive Dysfunction
Amanda Stueber, Carrie Cuttler
Journal of Attention Disorders (2021) Vol. 26, Iss. 6, pp. 942-955
Closed Access | Times Cited: 28
Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)
Kevin F. Boehnke, Winfried Häuser, Mary‐Ann Fitzcharles
Current Rheumatology Reports (2022) Vol. 24, Iss. 7, pp. 238-246
Open Access | Times Cited: 20
Medicinal cannabis for the treatment of anxiety disorders
Maximus Berger, G. Paul Amminger, Iain S. McGregor
Australian Journal of General Practice (2022) Vol. 51, Iss. 8, pp. 586-592
Open Access | Times Cited: 19
Anti-anxiety Properties of Selected Medicinal Plants
Asmatullah Khan, Muhammad Akram, Muthu Thiruvengadam, et al.
Current Pharmaceutical Biotechnology (2021) Vol. 23, Iss. 8, pp. 1041-1060
Closed Access | Times Cited: 23
A survey of medical cannabis use during perimenopause and postmenopause
Mary Kathryn Dahlgren, Celine El-Abboud, Ashley M. Lambros, et al.
Menopause The Journal of The North American Menopause Society (2022) Vol. 29, Iss. 9, pp. 1028-1036
Open Access | Times Cited: 16
Anxiety Modulation by Cannabinoids—The Role of Stress Responses and Coping
József Haller
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15777-15777
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top